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Abstract
Arsenic (+3 oxidation state) methyltransferase (AS3MT) is the key enzyme in the metabolism of 
inorganic arsenic (iAs). Polymorphisms of AS3MT influence adverse health effects in adults, but 
little is known about their role in iAs metabolism in pregnant women and infants. The 
relationships between seven single nucleotide polymorphisms (SNPs) in AS3MT and urinary 
concentrations of iAs and its methylated metabolites were assessed in mother-infant pairs of the 
Biomarkers of Exposure to ARsenic (BEAR) cohort. Maternal alleles for five of the seven SNPs 
(rs7085104, rs3740400, rs3740393, rs3740390, and rs1046778) were associated with urinary 
concentrations of iAs metabolites, and alleles for one SNP (rs3740393) were associated with birth 
outcomes/measures. These associations were strongly dependent upon the male sex of the fetus 
but independent of fetal genotype for AS3MT. These data highlight a potential sex-dependence of 
the relationships among maternal genotype, iAs metabolism and infant health outcomes.
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1. Introduction
Inorganic arsenic (iAs) is a developmental toxicant that crosses the placenta reaching fetal 
organs [1–3]. Exposure to iAs during pregnancy has been associated with adverse health and 
infant outcomes including increased risk of spontaneous abortion, stillbirth, infant mortality, 
low birth weight, decreased head and chest circumferences, and increased risk of infection in 
infants [4]. In addition to being associated with adverse outcomes in early life, prenatal and 
early childhood exposures to iAs have been associated with higher rates of mortality in 
adulthood [5]. There is increasing information that the detrimental health impacts of prenatal 
iAs exposure are associated not only with levels of exposure to iAs but also its 
biotransformation.
In humans, ingested iAs is biotransformed via multiple consecutive methylation steps into 
the methylated metabolites, monomethyl-arsenic (MMAs) and dimethyl-arsenic (DMAs), a 
process that has been described as enhancing removal and thus decreasing the overall 
toxicity of arsenic [6]. Both inorganic and methylated arsenicals have been detected in 
trivalent (AsIII) and pentavalent (AsV) oxidation states in the urine of subjects chronically 
exposed to arsenic [6, 7]. Notably, trivalent MMAsIII and DMAsIII have been shown to be 
more cytotoxic, genotoxic and potent inhibitors of some enzymes than their pentavalent 
counterparts [8], thus making them critical intermediate metabolites of adverse effects 
associated with iAs exposure. The urinary levels of excreted iAs and its metabolites are used 
to assess individual arsenic exposure and methylation efficiency. In general, individuals who 
are thought to be efficient in iAs methylation have lower percentages of total urinary arsenic 
present as iAs (10–20%) and MMAs (10–20%) and a higher percentage as DMAs (60–80%) 
[6]. Higher percentages of iAs and MMAs in urine may indicate poorer metabolism/
biotransformation of iAs and have been linked to some of the adverse health effects 
including cancer, and cardiovascular disease [9]. In relation to infant health, we have shown 
that higher urinary MMAs and %MMAs in pregnant women are associated with adverse 
health outcomes in infants, specifically lower birth weight [10]. Individual iAs methylation 
capacities vary across individuals and depend on other numerous factors, such as dose and 
duration of exposure to iAs, co-exposure to other toxicants, nutritional status, gender, age, 
and genetic factors [4, 9, 11, 12].
The biotransformation, i.e. methylation, of arsenic is conducted by the enzyme arsenic (+3 
oxidation state) methyltransferase (AS3MT) [13]. Confirming the central role of this enzyme 
in arsenic methylation, a dramatic decrease in arsenic methylation capacity has been 
observed in AS3MT knock-out mice and in HepG2 cells where it has been silenced [14, 15]. 
Additionally, single nucleotide polymorphisms (SNPs) in the AS3MT gene have been 
associated with altered arsenic methylation capabilities [16–20]. Further evidence supporting 
the role of AS3MT as a primary mediator of arsenic metabolism is a genome-wide 
association (GWAS) study in Bangladesh highlighting a strong association between arsenic 
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metabolism and the chromosome 10q24.32 region, the genomic location of AS3MT [21]. 
AS3MT polymorphisms have been associated with the metabolic patterns of iAs in 
individuals, and these patterns have been shown to differ among racial or ethnic groups [16, 
20]. AS3MT polymorphisms have also been associated with the level of AS3MT expression 
in peripheral blood [22].”
The aim of the present study was to examine the relationship and potential interactions 
between maternal and fetal genotypes for AS3MT examining seven targeted SNPs as they 
relate to iAs metabolism indicators and infant birth outcomes in the BEAR pregnancy cohort 
located in Goméz Palacio, Mexico [1, 10, 23, 24]. SNPs evaluated in this study have been 
previously shown to be associated with arsenic metabolism, AS3MT gene expression in 
blood, or iAs associated diseases [16, 18, 20–22, 25–37]. However, to date the relationships 
between maternal and fetal AS3MT genotypes as predictors of maternal metabolism and 
infant health outcomes have not been examined.
2. Materials and Methods
2.1 Ethics Statement, Study Subjects and Sample Collection
This study was approved by the Institutional Review Boards of the University of North 
Carolina at Chapel Hill and Universidad Juárez del Estado de Durango (UJED). A total of 
200 pregnant women residing in Gómez Palacio, in the State of Durango, Mexico, were 
recruited at the General Hospital of Gómez Palacio to participate in the BEAR prospective 
pregnancy cohort. At birth, cord blood serum samples and birth outcome measures were 
collected from all infants born to recruited mothers. Requirements for participation, 
recruitment information, sampling and determination of urinary and drinking water 
arsenicals, and birth outcome measures have been reported previously [10, 23]. Briefly, 
water samples were collected from the participants’ stated main source of drinking water by 
a member of the research team. The concentrations of DW-iAs were measured using hydride 
generation-atomic absorption spectrometry (HG-AAS) system as described previously [38, 
39]. The limit of detection (LOD) for DW-iAs was 0.456 mg/L. Maternal spot urine samples 
were collected at the time of delivery, immediately placed in a cryovial, and stored in liquid 
nitrogen. Samples were shipped at −80 C to the University of North Carolina at Chapel Hill 
(Chapel Hill, NC) for analysis. The specific gravity (SG) of each urine sample was measured 
using a handheld refractometer (Reichert TX 400 #13740000; Reichert Inc., Depew, NY). 
The major arsenical species, specifically iAs and its monomethylated and dimethylated 
metabolites (MMAs and DMAs), were measured using HG-AAS with cryotrapping [39, 40]. 
The LOD for urinary iAs, MMAs, and DMAs were 0.2 ng/mL, 0.1 ng/mL, and 0.1 ng/mL, 
respectively. U-tAs was defined as the SG-adjusted sum of iAs, MMAs (trivalent + 
pentavalent monomethylated arsenicals), and DMAs (trivalent + pentavalent dimethylated 
arsenicals). Each urine sample was adjusted using the following formula: (mean measured 
SG-1)/(individual measured SG-1) [41], where the mean SG of the cohort was 1.014 g/ml. 
Levels of arsenic in drinking water and urine that were below the LOD were converted to 
values according to the formula: LOD/(√2) [42]. We selected not to adjust by creatinine as it 
has been shown to be associated with arsenic methylation efficiency [12].
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2.2 DNA Isolation and Genotyping
DNA was isolated from the 200 maternal whole blood and 200 fetal cord blood samples 
using the QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, CA) according to the 
manufacturer’s protocol and stored at −80oC. Quality and concentration of DNA was 
evaluated on a NanoDrop 2000c UV-Vis spectrophotometer (Thermo Scientific). Seven 
polymorphisms in the AS3MT gene (ID: 57412; NM_020682.3; NP_065733.2) that have 
been previously associated with inter-individual differences in iAs metabolism and/or 
AS3MT expression were evaluated. These SNPs were evaluated using functionally tested 
(rs7085104, rs3740400, rs3740390, rs11191439, rs10748835, rs1046778) or validated 
(rs3740393) TaqMan assays purchased from AB Applied Biosystems (Foster City, CA). The 
ABI Dual 384-Well GeneAmp PCR System 9700 and ABI PRISM 7900HT Sequence 
Detection System from Applied Biosystems were used for genotyping and the ABI SDS 
software for data analysis. Here, 10% of randomly selected samples were used for a quality 
control assessment. In addition, 10% of samples were independently reanalyzed using the 
LightCycler® 480 Instrument (Roche) and genotypes evaluated by Endpoint Genotyping 
LC480 software.
2.3 Statistical Analysis
All statistical analyses were carried out using R [43]. SNP genotypes were numerically 
coded as zero (wild type homozygote, zero copies of the minor/less common allele), one 
(heterozygote, one copy of the minor allele) or two (variant homozygote, two copies of the 
minor allele). The Hardy-Weinberg equilibrium (HWE) test was performed for each SNP. 
Three women with missing genotype and/or birth outcome information were excluded from 
the analysis, bringing the final sample size to 197 mother-infant pairs (n=394 subjects). 
Allele frequencies were compared to two separate populations, located in San Antonio de 
los Cobres, Argentina and Matlab, Bangladesh, that had been previously genotyped for the 
seven SNPs in AS3MT [22].
Multiple linear regression was performed to examine the relationships between maternal 
and/or fetal alleles for each of the seven SNPs, six iAs metabolite levels/percentages and six 
birth outcomes/measures. The iAs metabolites investigated were U-iAs, U-MMAs, and U-
DMAs, and their percentages: %iAs, %MMAs and %DMAs. The six birth outcomes/
measures assessed were gestational age (wks), birthweight (g), birthweight/gestational age, 
placental weight (g), length (cm), and head circumference (cm). This allowed for 
comparisons to the primary predictors, maternal and/or fetal AS3MT genotype, while 
controlling for the effects of several important cofounders known to affect arsenic 
metabolism. A priori covariates were selected based on their known relationship to birth 
outcomes as well as metabolism. These factors included: U-tAs (total urinary arsenic as a 
measure of exposure), maternal age, smoking status, drinking status, and education level (a 
surrogate used for socioeconomic status). While there can be differences in iAs metabolism 
over pregnancy, all samples were collected at the time of birth thus minimizing metabolism 
differences during times of pregnancy [44, 45]. The data were analyzed for outliers and 
determined not to be influenced by outliers. Five models were constructed and tested. The 
primary model (Model I) included maternal AS3MT genotype as a predictor, controlling for 
fetal sex. Additionally, because there are known sex specific effects of arsenic on infant 
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biomarkers and birth outcomes [10, 46, 47], a fetal sex-stratified model was included (Model 
II). To investigate potential contributions from the fetal AS3MT genotypes, three additional 
models were used. Model III assessed the interaction between maternal and fetal genotypes. 
Model IV assessed maternal and fetal genotype individually, and Model V assessed fetal 
genotype alone. Beta (β) coefficients were calculated representing the estimated change in 
iAs metabolite levels or percentages or birth outcomes/measures given the addition of one 
copy of the minor allele. Specifically, heterozygotes were compared to the referent group, 
the wild type homozygous group carrying zero copies of the minor allele. As the SNPs 
analyzed were in high linkage disequilibrium, for all models an adjusted p-value threshold of 
≤0.01 was used for significance representing a correction for five tests (p=0.05/5) as detailed 
[48]. Additionally, because of this high linkage disequilibrium, a haplotype-based analysis 
was further performed using the R package, haplo.stats [49]. A permutation-based haplotype 
analysis was performed on all 21 possible SNP pairs, and on three selected three-SNP sets, 
with significance set at p≤0.05.
3. Results
3.1 Characteristics of the study population
Selected maternal demographic characteristics, indicators of iAs exposure, pregnancy and 
birth outcomes of the mother-infant pairs of BEAR cohort are described in Table 1 and 
reported in detail elsewhere [10]. Briefly, all 200 women participating in the study were of 
Hispanic origin, and with good overall health status. Their average age was 24 years, and 
most had singleton pregnancies. Among all births, 1.5% were preterm (<37 weeks). Male 
infants (52%) on average had a significantly (p = 0.0003) higher birth weight (3453 g) 
compared to females (3215 g). Of all infants, 2% were of low birth weight, 14% were small 
for gestational age, while approximately 10% were large for gestational age. The infants had 
an average length of 50 cm, and head circumference of 35 cm (Table 1).
Indicators of iAs exposure included the concentration of iAs in drinking water (μg/L; DW-
iAs) and maternal concentrations of iAs and its methylated metabolites measured in urine, 
MMAs and DMAs (μg/L; U-iAs, U-MMAs, and U-DMAs). Due to the instability of 
trivalent methylated arsenicals [37], only a sum of trivalent (AsIII) and pentavalent (AsV) 
arsenicals was measured. The levels of iAs in drinking water samples of the cohort ranged 
from the LOD of 0.46 μg/L up to 236 μg/L. Of these drinking water samples, 107 (53%) had 
DW-iAs that exceeded the WHO standard (10 μg/L) and 56 (28%) exceeded Mexico’s 
standard of 25 μg/L. The mean and median DW-iAs of the cohort were 24.6 μg/L and 13.0 
μg/L, respectively (Table 1). As with DW-iAs, a range of U-iAs, U-MMAs and U-DMAs 
was observed (Table 1). Most of the urine samples (95%) had detectable levels of U-iAs and 
U-MMAs with ranges of <LOD (0.2 μg/L)-23.0 μg/L and < 0.12 μg/L-18.2 μg/L, 
respectively. DMAs were detected in all urine samples and ranged from 1.4–292.5 μg/L. 
Total maternal urinary arsenic (U-tAs), defined as the sum of U-iAs, U-MMAs, and U-
DMAs, ranged from 4.30 μg/L to 319.7 μg/L. The average percents of the iAs metabolites 
with regard to U-tAs were 6.1% iAs, 6.4% MMAs, and 87.6% DMAs, which is in 
agreement with studies that report a generally higher methylation capacity of pregnant 
women as compared to non-pregnant women [6]. For this cohort, we have previously 
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reported a significant positive correlation between DW-iAs and U-tAs (r = 0.51; p<0.0001) 
[10].
3.2 Allele frequency assessment
The women and infants of the BEAR cohort were classified into one of three categories 
depending upon their genotypes as wild-type homozygotes (i.e., carriers of two copies of the 
major allele), variant homozygotes (carriers of two copies of the minor allele) or 
heterozygotes (carriers of one copy of the major allele and one copy of the minor allele). Six 
of the tested SNPs are located within intronic regions (rs7085104, rs3740400, rs3740393, 
rs3740390, rs10748835 and rs1046778) of AS3MT. One non-synonymous SNP present in 
exon nine alters the amino acid sequence of the AS3MT protein (rs11191439, Met287Thr). 
The SNP positions within the AS3MT gene and previously published associations between 
alleles within SNPs, iAs metabolism indicators, AS3MT expression, and health outcomes 
are summarized in Figure 1. A comparison of the allele frequencies for the BEAR cohort 
relative to genotype frequencies found in two independent cohorts, one in San Antonio de 
los Cobres, Argentinea (n=176) and one in Matlab, Bangladesh (n=359) are provided 
(Figure 2, Table 2) [22]. These data show that the allele frequencies of women in Goméz 
Palcio are generally concordant with those in Matlab, Bangladesh, but differ from those in 
San Antonio de los Cobres, Argentina. All examined SNPs passed the Hardy-Weinberg 
equilibrium test at p<0.05. Five pairs of SNPs, rs7085104 and rs3740400, rs3740400 and 
rs10748835, rs3740393 and rs3740390, rs7085104 and rs10748835, rs10748835 and 
rs1046778, were in strong linkage disequilibrium with r2 = 0.95, 0.75, 0.74, 0.72, and 0.71, 
respectively (Figure 3).
3.3.1 Association between maternal AS3MT genotype and arsenic metabolites
—For all alleles of each of the seven SNPs analyzed, multiple linear regression analyses 
were conducted using the models specified above. Associations were examined between 
maternal AS3MT alleles and urinary iAs metabolite levels and percentages (Table 3, 
Supplemental Table 1). Alleles of five of the seven SNPs (rs7085104, rs3740400, 
rs3740393, rs3740390, and rs1046778) showed significant (p<0.01) associations with U-
MMAs, U-DMAs, %MMAs, or %DMAs while rs11191439 showed no significance with 
iAs or any of the urinary metabolites (Table 3, Supplemental Table 1). Alleles of SNP 
rs10748835 showed marginally significant (p<0.05) associations with U-MMAs and 
%MMAs (Table 3). As indicated by the beta (β) coefficients presented in Table 3, lower U-
MMAs and %MMAs and higher U-DMAs and %DMAs were associated with the presence 
of the minor/less common allele for all alleles of these SNPs (Table 3). This general trend 
supports that the major maternal AS3MT alleles are associated with higher %MMAs and 
lower %DMAs in urine.
Associations between maternal alleles in AS3MT SNPs and maternal urinary arsenic 
metabolite levels and percentages were further stratified based upon the sex of the infant 
(Model II) (Table 3). Generally, associations between maternal AS3MT alleles and levels 
and %MMAs and %DMAs were significant if women were pregnant with a male child, but 
this was not the case for women pregnant with a female child. The presence of the minor 
allele in rs1191439 (Met287Thr) in women pregnant with a male, but not female, child was 
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associated with increased U-MMAs and %MMAs and decreased U-DMAs and %DMAs. 
Interestingly, this is the opposite relationship as was observed for the intronic SNPs, 
rs7085104, rs3740400, rs3740393, rs3740390, and rs1046778, where the minor allele was 
associated with decreased U-MMAs and %MMAs and increased U-DMAs and %DMAs. 
Taken together, significant negative associations were observed between the minor alleles 
and %MMAs and positive associations between the minor alleles and %DMAs for all tested 
genotypes, with this relationship inverted for alleles of SNP rs11191439. No significant 
associations were found between maternal SNPs and urinary arsenic metabolite levels when 
women were pregnant with a female child (Table 3, Supplemental Table 1). The stratified 
analyses highlight a strong relationship between maternal genotype and fetal sex, with 
significant associations between maternal alleles of AS3MT SNPs, urinary arsenic 
metabolites, and birth outcomes in women pregnant with males.
3.3.2 Association between maternal AS3MT genotype and birth outcome/
measures—Maternal alleles of AS3MT SNPs were also compared to six birth outcomes/
measures (Table 4, Supplemental Table 2). Statistical significance was observed between 
alleles of rs3740393 and placental weight (β=40.873, p=0.0056). Alleles of this same SNP 
showed a marginally significant (p=0.02) relationship to birthweight. The majority of 
relationships observed between maternal alleles of AS3MT and birth outcomes/measures 
were only marginally significant (p≤0.05). Overall, fewer significant associations were seen 
between maternal alleles of AS3MT and birth outcomes than between alleles and maternal 
urinary arsenic metabolite levels. Notably, for the majority of the alleles tested, there were 
positive associations between the minor alleles and birth outcomes/measures.
Subsequently, associations between AS3MT alleles and birth outcomes/measures were 
stratified based upon the sex of the infant (Model II) (Table 4, Supplemental Table 2). 
Several birth outcomes were marginally significant (p≤0.05) in relationship to AS3MT 
genotype when stratified by fetal sex. Alleles of three SNPs (rs3740393, rs10748835 and 
rs1046778) were marginally significant (p≤0.05) and positively associated with gestational 
age among women pregnant with male infants. Additionally, women pregnant with male 
infants showed a marginally significant (p≤0.05) positive association between alleles of 
rs10748835 and length at birth (Table 4). In the case of women pregnant with female infants, 
alleles of rs3740390 and rs3740393 were positively associated with placental weight (Table 
4, Supplemental Table 2).
3.4.1 Association between maternal and fetal AS3MT genotypes and arsenic 
metabolites—Based on the sex-specific nature of the relationship between maternal 
AS3MT genotype and maternal metabolism, we set out to investigate whether fetal genotype 
might influence maternal iAs metabolism. First, a full model with main effects of both 
maternal and fetal AS3MT genotypes and their interactions was considered (Model III, 
Supplemental Table 1). Interestingly, most of the interactions between maternal and fetal 
genotypes were insignificant in their relationship to maternal iAs metabolism. A marginally 
significant (p=0.0188) maternal-fetal genotype interaction was observed for SNP 
rs10748835 with %MMAs. The full model was subsequently reduced by removing the 
interaction term to further determine the contribution of fetal genotype (Model IV). Only the 
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maternal AS3MT alleles showed statistical significance in association with maternal iAs 
metabolism indicators (Supplemental Table 1). Finally, the impact of fetal AS3MT genotype 
alone was tested with no significant associations found with iAs metabolism indicators 
(Model V) (Supplemental Table 1).
3.4.2 Association between maternal and fetal AS3MT genotypes and birth 
outcome/measures—We next investigated whether fetal AS3MT genotype is associated 
with infant outcomes/measures using the same models described above. As observed in the 
tests for association with maternal iAs metabolism indicators, there were no statistically 
significant results when testing the interaction between maternal and fetal genotypes 
(Supplemental Table 2). The reduced model used to examine the maternal and fetal AS3MT 
genotypes separately (Model IV) showed that only the maternal AS3MT genotypes showed 
statistical significance in association with infant outcomes/measures. Fetal alleles for 
rs3740390 and rs1046778 showed marginal significance (p=0.0157 and 0.0381, 
respectively) with placental weight. Finally, when considering the impact of fetal genotype 
for AS3MT alone (Model V), there were two significant associations between placental 
weight and fetal alleles of rs3740390 (p=0.0024) and rs1046778 (p=0.0097). Additionally, 
alleles for two fetal SNPs, rs37430400 and rs3740393 showed marginally significant 
associations with placental weight (p=0.0500 and 0.0157, respectively).
3.5 Association of maternal AS3MT haplotypes with urinary arsenicals and birth outcomes
Haplotype analysis was also conducted on all possible SNP-pairs and three selected three-
SNP sets. The comparison of paired haplotypes showed results similar to the analysis of the 
alleles of individual SNPs. The majority of associations for pairwise haplotypes were found 
between maternal U-MMAs and %MMAs, with 19 out of 21 pairwise comparisons showing 
significant association with U-MMAs, and all 21 pairwise comparisons associated with 
%MMAs (Supplemental Table 3). Typically, haplotypes where the SNP pair consisted of 
both major alleles were associated with increased U-MMAs and %MMAs, while haplotypes 
where the SNP pair consisted of both minor alleles were associated with decreased U-
MMAs and %MMAs, indicating the additivity of the SNPs. This is also confirmed by the 
observation that haplotypes where the SNP pair consisted of one major allele and one minor 
allele typically resulted in non-significant results. In relation to DMAs, seven of the pairwise 
comparisons were associated with U-DMAs and 10 of the pairwise comparisons were 
associated with %DMAs (Supplemental Table 3). Specifically, major allele haplotypes were 
associated with decreased U-DMAs and %DMAs, minor allele haplotypes were associated 
with increased U-DMAs and %DMAs and heterozygote allele haplotypes were typically 
nonsignificant. There were no associations found between U-iAs or %iAs for any of the 
pairwise haplotype analyses. While there were fewer associations between pairwise 
haplotypes and birth outcomes, a total of six of the pairwise haplotypes displayed an 
association with either birthweight, birthweight/gestational age, or placental weight 
(Supplemental Table 3).
The three-SNP cluster haplotypes were determined based upon their linkage disequilibrium 
coefficients (Figure 3). All three haplotypes were associated with %MMAs. Specifically, 
major allele haplotypes were associated with elevated %MMAs, and minor allele haplotypes 
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were associated with reduced %MMAs (Supplemental Table 4). There were two significant 
associations between placental weight and birthweight/gestational age and the cluster 
consisting of rs7085104/rs3740400/rs1046778. No other cluster displayed a significant 
relationship with any of the birth outcomes/measures (Supplemental Table 4).
4. Discussion
We have recently demonstrated that iAs metabolism in pregnant women is associated with 
differential health outcomes in infants, where elevated U-MMAs ad %MMAs in maternal 
urine were associated with lower birth weight [10]. To examine whether this metabolism and 
subsequent birth outcomes is influenced by maternal and/or fetal genotype, we focused on 
polymorphisms within the primary gene associated with iAs metabolism, namely AS3MT 
[13, 14]. Such nucleotide differences have been shown to alter the efficiency of the iAs 
metabolism as measured in urinary metabolite profiles [22, 27]. Seven SNPs in AS3MT 
were targeted for analysis because of their known associations with iAs metabolism, 
AS3MT expression and/or diseases [16, 18, 20–22, 25–37]. The results demonstrate that 
maternal genotype for AS3MT is associated both with maternal metabolism iAs and to 
infant birth outcomes/measures, albeit to a lesser extent. Interestingly, we also demonstrate 
that the association between maternal AS3MT genotype and maternal iAs metabolism 
profiles was strong when women were pregnant with a male fetus, a finding that was 
independent of fetal genotype for AS3MT. This suggests that the sex-specific effects that 
were observed are not driven by fetal genotype of AS3MT. To our knowledge this is the first 
study to simultaneously examine the relationship of maternal and fetal AS3MT genotype 
with urinary arsenic metabolites in pregnant women and infant health outcomes.
We demonstrate that alleles for five of the seven SNPs (rs7085104, rs3740400, rs3740393, 
rs3740390, and rs1046778) were associated with iAs metabolism indicators. In the present 
study we observed that the minor alleles for these SNPs were associated with lower 
%MMAs and higher %DMAs. In contrast, the major or more common alleles were 
associated with higher %MMAs and lower % DMAs suggesting that the majority of 
individuals in the cohort are at greater risk for an elevated urinary MMA phenotype. This 
finding is of concern given the known links between elevated %MMAs and detrimental 
health outcomes including premalignant skin lesions, DNA damage in children and 
increased risk for bladder cancer [26, 35, 36]. Additionally, elevated levels and proportions 
of MMAs, have been associated with poorer fetal health outcomes, specifically lowered birth 
weight in this same cohort [10].
The observation that the minority of subjects carry alleles for a lower urinary MMA 
phenotype is similar to previous studies that have shown that the minor alleles for six of the 
SNPs (rs7085104, rs3740400, rs3740393, rs3740390, rs10748835 and rs1046778) evaluated 
are associated with lower %iAs and %MMAs and higher %DMAs in urine [11, 17, 22, 26–
34, 50]. The only currently known exception is the Andean population in San Antonio de los 
Cobres, Argentina, where the majority of the subjects have been shown to carry AS3MT 
alleles associated with a reduced urinary MMA phenotype [20, 22, 27, 51]. The data from 
the present study highlight that the individuals with the minor alleles for rs7085104, 
rs3740400, rs3740393, rs3740390, rs10748835, and rs1046778, representing only 8–39% of 
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women in total, have lower %MMAs in urine. In contrast to the findings for the alleles of the 
majority of the SNPs tested which showed an association between the minor allele and lower 
U-MMAs and %MMAs and higher U-DMAs and %DMAs, the minor or less common allele 
for the Met287Thr polymorphism was associated with higher levels of U-MMAs and 
%MMAs and lower levels of U-DMAs and %DMAs. In the present study, alleles of four of 
the SNPs including rs3740400, rs3740393, rs3740390, and rs1046778 were also nominally 
associated with birth outcomes including birth weight, placental weight, or length at birth. 
Here the relationships between the minor alleles and the birth outcomes were generally 
positively associated (i.e., increased birth weight, increased placental weight, increased 
length at birth) along with the previously demonstrated lower proportions of MMAs and 
higher proportions of DMAs. The results from the present study suggest that a pregnant 
woman’s ability to metabolize iAs is dependent upon her AS3MT genotype and this 
metabolism influences the health of her unborn child.
Interestingly, fetal sex-stratified analysis revealed stronger associations between maternal 
genotype for AS3MT and maternal metabolites when women were pregnant with a male 
fetus. As determined through fetal AS3MT genotype testing, this effect was not related to 
the fetal genotype of AS3MT. After stratifying for the sex of the infant, alleles for six of the 
SNPs were significantly associated with metabolite levels in mothers pregnant with male 
fetuses, in strong contrast to no alleles showing association with iAs metabolite levels in 
mothers pregnant with female fetuses. As with the overall analysis, for women carrying male 
fetuses, the minor AS3MT alleles were associated with lower %MMAs and higher %DMAs, 
while women carrying female fetuses showed no significant associations between maternal 
genotype and maternal iAs metabolites. Sex-specific differences have been associated with 
arsenic exposure. For example, early-life exposure to arsenic has been shown to increase the 
incidence of cancer, cardiovascular disease, and pulmonary outcomes in sex-specific manner 
[52–54]. Taken together, this finding suggests that mothers may metabolize arsenic 
differently not only based upon their genotype for AS3MT but also depending upon whether 
they are pregnant with a female or male fetus. While further research is needed to determine 
a mechanism that may underlie this effect, the influence of sex hormones or involvement of 
certain sex-specific signaling pathways are likely to underlie these effects. These 
observations from the present study support a growing body of literature highlighting sex-
specific differences in response to prenatal arsenic exposure.
While this study demonstrates novel findings of associations between maternal genotypes 
for AS3MT, iAs metabolism indicators and birth outcomes/measures, it is not without 
limitations. In the present study we did not directly control for seafood consumption which 
can influence U-DMA levels [55]. However, previous analyses within this cohort showed 
that seafood consumption did not significantly affect the association between iAs metabolite 
levels and birth outcomes [10]. Additionally, while we controlled for factors known to 
influence iAs exposure in our analysis, we were unable to control for differences in distinct 
nutritional status/habits of specific population, particularly nutrients known to affect iAs 
metabolism.
This study is the first to report significant associations between maternal alleles of AS3MT 
genotype and sex-specific effects on maternal iAs metabolites and infant birth outcomes. 
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Although this study does not provide a precise molecular mechanism underlying these 
effects on infant birth outcomes, it supports that specific maternal metabolic profiles of 
arsenic depend on AS3MT genotype and that these are influenced by the sex, but not the 
AS3MT genotype, of the fetus. Further studies are needed to evaluate the potential long-
lasting effects of prenatal iAs exposure on children’s health and determine how to best 
predict and protect those at increased risk for detrimental health effects.
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Highlights
• Maternal genotype for AS3MT is linked to maternal metabolism iAs 
and to infant birth outcomes/measures.
• Associations between maternal AS3MT genotype and maternal iAs 
metabolism profiles was strong when women were pregnant with a 
male fetus.
• Fetal genotype was not linked to changes in maternal iAs metabolism 
or infant birth outcomes/measures.
• The minor/less common allele was associated with decreased U-
MMAs/%MMAs and increased U-DMAs/%DMAS.
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Figure 1. 
Position of single nucleotide polymorphisms (SNPs) within the AS3MT gene and known 
associations with iAs biotransformation and health outcomes. Arrows indicate the region of 
the SNP locations within the gene. Light blue rectangles represent the 11 exonic regions of 
the gene.
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Figure 2. 
Allelic frequency comparison of the Goméz Palacio, Mexico cohort to populations in San 
Antonio de los Cobres, Argentinea (n=176) or Matlab, Bangladesh (n=359) as detailed in 
[22].
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Figure 3. 
Linkage disequilibrium values (R-squared) for seven AS3MT polymorphisms in the Goméz 
Palacio, Mexico cohort.
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Table 1
Selected demographic characteristics and iAs exposure indicators of the BEAR study.
Characteristic n (%)+ Mean, Median (Range)
 Maternal Age at Delivery (years) - 24, 23 (18–41)
 Education
  Less than High School 50 (25.1%) -
  High School or Above 149 (74.5%) -
 Smoking Status During Pregnancy
  Non-smokers 186 (93.0%) -
  Current smokers 13 (7.0%) -
 Alcohol Consumption During Pregnancy
  None 159 (79.5%) -
  Some 41 (20.5%) -
 Seafood Consumption During Pregnancy
  None 155 (78.3%) -
  Some 43 (21.7%) -
 Infant Sex
  Male 104 (52.0%) -
  Female 96 (48.0%) -
Birth Outcomes
 Gestational Age (weeks)
  All - 39, 40 (34–42)
  <37 weeks (preterm) 3 (1.5%) -
  >37 weeks (not preterm) 197 (98.5%) -
 Birth weight (g)
  All - 3339, 3355 (1800–5120)
  Male - 3453, 3490 (2100–5120)*
  Female - 3215, 3150 (1800–4200)
 Low Birth Weight (LBW) 4 (2.0%) -
 Small for Gestational Age (SGA) 28 (14.0%) -
 Large for Gestational Age (LGA) 19 (9.5%) -
 Placental Weight (g) - 648, 640 (390–1070)
 Length (cm) - 50, 50 (40–59)
 Head Circumference (cm) - 35, 35 (31–38)
Exposure measures
 DW-iAs (μg/L) - 24.6, 13.0 (<LOD#- 236.0)
 U-tAs (μg/L) - 37.5, 23.3 (4.3–319.7)
Metabolism of Arsenic Indicators
 U-iAs (μg/L) - 2.1, 1.3 (<LOD#-23.0)
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Characteristic n (%)+ Mean, Median (Range)
 U-MMAs (μg/L) - 2.3, 1.4 (0.12–18.2)
 U-DMAs (μg/L) - 33.1, 20.6 (1.4–292.5)
 iAs (%) - 6.1, 5.3 (0.77–45.1)
 MMAs (%) - 6.4, 6.0 (0.68–24.9)
 DMAs (%) - 87.6, 88.5 (32.7–96.7)
+
Differences in n based on missing demographic data.
*Significant difference in means (p=0.0003) between males and females.
#
Limit of detection (LOD) for DW-iAs=0.46 μg/L
#
Limit of detection (LOD) for U-iAs=0.2 μg/L
#
Limit of detection (LOD) for U-MMAs=0.1 μg/L
#
Limit of detection (LOD) for U-DMAs=0.1 μg/L
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